Clinical Heterogeneity and Transitions of Obesity in Mexico Academic Article in Scopus uri icon

abstract

  • Context: There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated comorbidities are lacking. Objective: We estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years. Methods: We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS), which assesses 3 dimensions (medical, mental, and functional) across 5 incremental severity stages, by sex and age groups, were estimated across all included surveys. Metabolically healthy obesity (MHO) was defined as the absence of diabetes, dyslipidemia, and hypertension. Results: A total of 20 758 participants were analyzed. Mean body mass index (BMI) increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among MHO individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, MHO was less likely as age and BMI increased. Conclusion: The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the aging of the population will cause additional burdens to the population and the health system. © The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved.

publication date

  • November 1, 2025